On the stock market since 2011, it operates in the world of health and science. It has 389 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Revenue is spread across several lines; no single product carries the company.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
Business Quality: Profit power and business quality trail similar companies in the sector.
angles, checked one by one.
The 5 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 91% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $187.6M in the vault; even if every debt were paid off, $156.7M would remain.
Over the last 12 months, company executives reported 39 buys and 15 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $3.25 — 400% above today’s price.
A loss of $74.9M against $85.3M in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.65. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
On our five-subject report card, LAB sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: LAB is a small company that closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (32/100) says the stock isn’t cheap.